ProCE Banner Activity

Current and Emerging Clinical Strategies for Pancreatic Cancer Treatment

Multimedia
In this on-demand Webcast from a live Webinar, expert faculty discuss best practices in treating patients with resectable and advanced pancreatic cancer and provide a look ahead at emerging therapeutic strategies that may soon change practice.

Released: March 11, 2021

Expiration: March 10, 2022

Share

Faculty

Michael J. Pishvaian

Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

Rachna Shroff

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Ipsen Biopharmaceuticals Inc

Learning Objectives

  • Apply individualized treatment strategies for the selection and sequencing of therapies for localized and advanced pancreatic cancer
  • Examine the role of PARP inhibitor maintenance after first-line platinum-based chemotherapy for patients with newly diagnosed pancreatic cancer and a germline BRCA mutation
  • Appraise the rationale and available/emerging data for the use of emerging and investigational therapies (novel chemotherapy platforms, PARP inhibitor, immunotherapy and immunotherapy-based combinations, stroma-targeting agents, tumor treating fields therapy, and others) and integrate into treatment planning as clinically applicable
  • Incorporate strategies to effectively identify and manage disease-related and treatment-related adverse events to support quality of life and continuation of therapy

Faculty Disclosure

Primary Author

Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

Michael J. Pishvaian, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Merck, and Seattle Genetics and has ownership interest in Perthera.

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Rachna T. Shroff, MD, has disclosed that she has received consulting fees from Agios/Clovis, Debiopharm, Exelixis, Incyte, Merck, QED Therapeutics, and Seattle Genetics and funds for research support from Exelixis, Merck, Pieris, Rafael, and Taiho.

Staff Disclosure

Staff

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.